Trabert B, et al. - Researchers analyzed data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3) to determine the associations of analgesic use with ovarian cancer in the prospective study. A slightly lower risk of developing ovarian cancer was observed among women who use aspirin daily (∼10% lower than infrequent/nonuse)—similar to the risk reduction observed in case–control analyses. Further study is needed to explain the observed potential elevated risks for 10+ years of frequent aspirin and nonsteroidal anti-inflammatory drugs, however, this could be due to confounding by medical indications for use or variation in drug dosing.

• Researchers studied 758,829 women who at study enrollment self-reported analgesic use in this work; 3514 of these developed ovarian cancer.
• Associations between frequent medication use and risk of ovarian cancer were assessed using Cox regression.
• They evaluated dose and duration in addition.
• They performed two-sided statistical tests in this work.

• Researchers observed a 10% reduction in ovarian cancer risk among women who used aspirin almost daily (≥6 days/wk) vs infrequent/nonuse (rate ratio [RR] = 0.90, 95% confidence interval [CI] = 0.82 to 1.00, P=.05).
• The risk was not identified to be associated with the frequent use (≥4 days/wk) of aspirin (RR = 0.95, 95% CI = 0.88 to 1.03), nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs; RR = 1.00, 95% CI = 0.90 to 1.11), or acetaminophen (RR = 1.05, 95% CI = 0.88 to 1.24).
• Elevated ovarian cancer risk was noted in correlation with daily acetaminophen use (RR = 1.28, 95% CI = 1.00 to 1.65, P=.05).
• Modestly elevated risk estimates were noted for frequent, long-term (10+ years) use of aspirin (RR = 1.15, 95% CI = 0.98 to 1.34) or nonaspirin NSAIDs (RR = 1.19, 95% CI = 0.84 to 1.68), although these were not statistically significant.